
    
      Phase I open-label dose escalation study of intravaginal artesunate, formulated in
      suppositories, in adult females with biopsy-confirmed CIN2/3. Thirty (30) subjects will
      undergo up to a total of three cycles of intravaginal artesunate. The first cycle will be
      initiated on Day 0, the second at Week 4, and the third and final cycle at week 8.
    
  